Nephrotoxicity from cancer immunotherapy

G. M. Dosik, J. U. Gutterman, Evan M Hersh, M. Akhtar, T. Sonoda, R. G. Horn

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Because systemic intravenous immunotherapy with Corynebacterium parvum is an effective immunopotentiating and immunotherapeutic agent in animals, clinical studies of this agent have been undertaken. Toxicities in man have been noted, but most are treated symptomatically. Three patients with metastatic melanoma developed oliguria, edema, diffuse bilateral pulmonary infiltrates, azotemia, hypoalbuminemia and hypocomplementemia, while receiving intravenous C. parvum therapy. All had renal biopsies that showed a proliferative glomerulonephritis with subendothelial basement membrane deposits. Immunofluorescence showed glomerular IgG, IgA, IgM, and the C3 component of complement. A fourth patient was found in retrospective chart review of 87 patients registered on two C. parvum-containing protocols. The frequency of the complication in this group was 3/87. Renal failure resolved in all four patients spontaneously after the cessation of C. parvum immunotherapy. Serial evaluation of renal function should be carried out in all patients on systemic adjuvant immunotherapy.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalAnnals of Internal Medicine
Volume89
Issue number1
StatePublished - 1978
Externally publishedYes

Fingerprint

Propionibacterium acnes
Immunotherapy
Neoplasms
Azotemia
Oliguria
Kidney
Hypoalbuminemia
Complement C3
Glomerulonephritis
Basement Membrane
Immunoglobulin A
Renal Insufficiency
Fluorescent Antibody Technique
Immunoglobulin M
Melanoma
Edema
Immunoglobulin G
Biopsy
Lung
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dosik, G. M., Gutterman, J. U., Hersh, E. M., Akhtar, M., Sonoda, T., & Horn, R. G. (1978). Nephrotoxicity from cancer immunotherapy. Annals of Internal Medicine, 89(1), 41-46.

Nephrotoxicity from cancer immunotherapy. / Dosik, G. M.; Gutterman, J. U.; Hersh, Evan M; Akhtar, M.; Sonoda, T.; Horn, R. G.

In: Annals of Internal Medicine, Vol. 89, No. 1, 1978, p. 41-46.

Research output: Contribution to journalArticle

Dosik, GM, Gutterman, JU, Hersh, EM, Akhtar, M, Sonoda, T & Horn, RG 1978, 'Nephrotoxicity from cancer immunotherapy', Annals of Internal Medicine, vol. 89, no. 1, pp. 41-46.
Dosik GM, Gutterman JU, Hersh EM, Akhtar M, Sonoda T, Horn RG. Nephrotoxicity from cancer immunotherapy. Annals of Internal Medicine. 1978;89(1):41-46.
Dosik, G. M. ; Gutterman, J. U. ; Hersh, Evan M ; Akhtar, M. ; Sonoda, T. ; Horn, R. G. / Nephrotoxicity from cancer immunotherapy. In: Annals of Internal Medicine. 1978 ; Vol. 89, No. 1. pp. 41-46.
@article{7293343a3ae043e2b3b172614ea904ab,
title = "Nephrotoxicity from cancer immunotherapy",
abstract = "Because systemic intravenous immunotherapy with Corynebacterium parvum is an effective immunopotentiating and immunotherapeutic agent in animals, clinical studies of this agent have been undertaken. Toxicities in man have been noted, but most are treated symptomatically. Three patients with metastatic melanoma developed oliguria, edema, diffuse bilateral pulmonary infiltrates, azotemia, hypoalbuminemia and hypocomplementemia, while receiving intravenous C. parvum therapy. All had renal biopsies that showed a proliferative glomerulonephritis with subendothelial basement membrane deposits. Immunofluorescence showed glomerular IgG, IgA, IgM, and the C3 component of complement. A fourth patient was found in retrospective chart review of 87 patients registered on two C. parvum-containing protocols. The frequency of the complication in this group was 3/87. Renal failure resolved in all four patients spontaneously after the cessation of C. parvum immunotherapy. Serial evaluation of renal function should be carried out in all patients on systemic adjuvant immunotherapy.",
author = "Dosik, {G. M.} and Gutterman, {J. U.} and Hersh, {Evan M} and M. Akhtar and T. Sonoda and Horn, {R. G.}",
year = "1978",
language = "English (US)",
volume = "89",
pages = "41--46",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Nephrotoxicity from cancer immunotherapy

AU - Dosik, G. M.

AU - Gutterman, J. U.

AU - Hersh, Evan M

AU - Akhtar, M.

AU - Sonoda, T.

AU - Horn, R. G.

PY - 1978

Y1 - 1978

N2 - Because systemic intravenous immunotherapy with Corynebacterium parvum is an effective immunopotentiating and immunotherapeutic agent in animals, clinical studies of this agent have been undertaken. Toxicities in man have been noted, but most are treated symptomatically. Three patients with metastatic melanoma developed oliguria, edema, diffuse bilateral pulmonary infiltrates, azotemia, hypoalbuminemia and hypocomplementemia, while receiving intravenous C. parvum therapy. All had renal biopsies that showed a proliferative glomerulonephritis with subendothelial basement membrane deposits. Immunofluorescence showed glomerular IgG, IgA, IgM, and the C3 component of complement. A fourth patient was found in retrospective chart review of 87 patients registered on two C. parvum-containing protocols. The frequency of the complication in this group was 3/87. Renal failure resolved in all four patients spontaneously after the cessation of C. parvum immunotherapy. Serial evaluation of renal function should be carried out in all patients on systemic adjuvant immunotherapy.

AB - Because systemic intravenous immunotherapy with Corynebacterium parvum is an effective immunopotentiating and immunotherapeutic agent in animals, clinical studies of this agent have been undertaken. Toxicities in man have been noted, but most are treated symptomatically. Three patients with metastatic melanoma developed oliguria, edema, diffuse bilateral pulmonary infiltrates, azotemia, hypoalbuminemia and hypocomplementemia, while receiving intravenous C. parvum therapy. All had renal biopsies that showed a proliferative glomerulonephritis with subendothelial basement membrane deposits. Immunofluorescence showed glomerular IgG, IgA, IgM, and the C3 component of complement. A fourth patient was found in retrospective chart review of 87 patients registered on two C. parvum-containing protocols. The frequency of the complication in this group was 3/87. Renal failure resolved in all four patients spontaneously after the cessation of C. parvum immunotherapy. Serial evaluation of renal function should be carried out in all patients on systemic adjuvant immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0017826289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017826289&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 41

EP - 46

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -